Harmon Cyrus 4

What Happened Harmon Cyrus, a director of Olema Pharmaceuticals (OLMA), received a derivative award on June 18, 2026 covering 29,500 shares. The Form 4 reports an acquisition price of $0.00 (derivative), indicating a grant of equity-based compensation rather than a cash purchase or sale. No immediate cash value or post-transaction ownership total is provided in the disclosed data.

Key Details

• Transaction date: 2026-06-18 (Grant/Award — derivative)
• Amount: 29,500 shares; Reported price: $0.00
• Filing date: 2026-06-23 — appears to be filed after the standard two-business-day Form 4 deadline (i.e., likely late)
• Shares owned after transaction: Not reported in the provided filing summary
• Footnote: Shares subject to the option vest in 12 equal monthly installments starting June 18, 2026; any unvested portion will vest in full on the issuer's next annual meeting if not otherwise fully vested, subject to continuous service.

Context This is an equity grant (derivative award) tied to service-based vesting; it does not represent an open-market purchase or sale. Grants are typically part of compensation or director incentive arrangements and should be interpreted accordingly. The late filing may be notable for compliance tracking but does not by itself indicate market action.